News2020-10-30T03:43:59+00:00

News

Keep abreast of our latest news and updates

From press releases to new product developments and announcements, come back often to read about the latest innovations here at NATX.

Aegis Life and Entos will use NTC’s proprietary Nanoplasmid™ plasmid DNA technology and manufacturing platform for the clinical and commercial production of their SARS-CoV-2 vaccine

As part of a new agreement with Nature Technology Corporation (NTC), Aegis Life and Entos will use NTC's proprietary Nanoplasmid™ plasmid DNA technology and manufacturing platform for the clinical and commercial production of their SARS-CoV-2 vaccine...

Poseida Therapeutics utilizes Nanoplasmid® technology to demonstrate increased transposition frequency

Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today will present data related to its proprietary manufacturing process designed to optimize its CAR-T product candidates. The Company will also illustrate the impact of these optimizations with preclinical data and preliminary clinical analysis with a focus on P-BCMA-101, its autologous CAR-T product candidate for multiple myeloma. The findings will be presented today at CAR-TCR Digital Week 2020 being held September 14-17, 2020.

Nanoplasmid is an ideal vector: Used by over 50 gene therapy companies worldwide

Small Backbone • Fast • Economical • Antibiotic-Free • Scalable

Go to Top